… dismutase 1 and sporadic amyotrophic lateral sclerosis: analysis of 155 … in a sporadic
amyotrophic lateral sclerosis patient. Mol. Cell. … Amyotrophic lateral sclerosis in an urban setting: a …

… The clinical implication of these findings is that promising therapeutic approaches can be
derived from multidrug treatments aimed at the simultaneous interception of damage in both …

… of a variety of medical experts in related fields. … therapy Riluzole is an antagonist to glutamate
release and is the only disease-modifying drug approved for ALS by the US Food and Drug …

… Multiple Sclerosis (MS) or Amyotrophic Lateral Sclerosis (ALS). In this instance, adipose
tissue has no homology to the diseased tissues, and the logic then is that non-homologous use …

… We describe progress for neurological disease treatment with MSC transplants. We
discuss data on amyotrophic lateral sclerosis (ALS) and on lysosomal storage diseases (Hurler …

… Neurological diseases such as amyotrophic lateral sclerosis (… of new drugs and/or drug
screening for ALS treatment and … a potential therapeutic target in amyotrophic lateral sclerosis. …

… drug AmX0035 has beneficial effects on survival and function in people with amyotrophic
lateral sclerosis (… The two drugs individually exhibit neuroprotective properties in experimental …

… treatment has been found for amyotrophic lateral sclerosis (… the disease, multiple medical
therapies have been proposed … translational researches from bench to bedside in various …

… Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are common
neurodegenerative disorders that are relentlessly progressive, fatal, and without effective treatment, …

… the small study sample and the low treatment doses received by patients. Another silencing
… RNAi therapy from the bench to the bedside is the lack of an in vivo biomarker of therapeutic …